Indication

For the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors.

Medicine details

Medicine name:
entrectinib (Rozlytrek)
SMC ID:
SMC2294
Pharmaceutical company
Roche/GSK
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
11 January 2021
SMC meeting date:
01 December 2020
Patient group submission deadline:
05 October 2020